These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11306468)

  • 1. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
    Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
    Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
    Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
    Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
    Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
    Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
    Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
    Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
    Brinkman A; van der Flier S; Kok EM; Dorssers LC
    J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analyses of mechanistic differences among antiestrogens.
    Wijayaratne AL; Nagel SC; Paige LA; Christensen DJ; Norris JD; Fowlkes DM; McDonnell DP
    Endocrinology; 1999 Dec; 140(12):5828-40. PubMed ID: 10579349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.
    Shibata T; Watari K; Izumi H; Kawahara A; Hattori S; Fukumitsu C; Murakami Y; Takahashi R; Toh U; Ito KI; Ohdo S; Tanaka M; Kage M; Kuwano M; Ono M
    Cancer Res; 2017 Jan; 77(2):545-556. PubMed ID: 27879270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
    Wittmann BM; Sherk A; McDonnell DP
    Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
    Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
    Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
    Fujita T; Kobayashi Y; Wada O; Tateishi Y; Kitada L; Yamamoto Y; Takashima H; Murayama A; Yano T; Baba T; Kato S; Kawabe Y; Yanagisawa J
    J Biol Chem; 2003 Jul; 278(29):26704-14. PubMed ID: 12738788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.